CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01223235
NCT01223235N/ACompleted
CompareCT.gov

A PILOT STUDY OF A POLYVALENT VACCINE-KLH CONJUGATE + OPT-821 GIVEN IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN SECOND OR GREATER COMPLETE OR PARTIAL CLINICAL REMISSION

Memorial Sloan Kettering Cancer Center·interventional·Posted Oct 18, 2010·Updated Jun 12, 2018

In Brief

A clinical study evaluating bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 for Fallopian Tubes Cancer and 2 related conditions. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells. The purpose of this study is to test whether it is safe to treat the cancer with a vaccine and another drug called bevacizumab (also known as Avastin).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 18, 2010
Enrollment StartOct 1, 2010
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 15.7 years ago

Interventions

bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821biological

A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.